share_log

Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q1 2024 Earnings Conference

Earnings Call Summary | Esperion Therapeutics(ESPR.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Esperion Therapeutics (ESPR.US) 2024 年第一季度業績會議
富途資訊 ·  05/07 23:06  · 電話會議

The following is a summary of the Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript:

以下是Esperion Therapeutics, Inc.(ESPR)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Esperion Therapeutics reported a record Q1 2024 revenue of $137.7 million, thanks to a $100 million litigation-related settlement from DSE.

  • US net revenue increased by 46% YoY to $24.8 million, powered by a 43% increase in retail prescription equivalents.

  • The company closed Q1 with $226.6 million in cash and cash equivalents.

  • Esperion Therapeutics報告稱,2024年第一季度收入創下了創紀錄的1.377億美元,這要歸功於DSE達成的1億美元訴訟相關和解協議。

  • 受零售處方等價物增長43%的推動,美國淨收入同比增長46%,達到2480萬美元。

  • 該公司在第一季度結束時擁有2.266億美元的現金及現金等價物。

Business Progress:

業務進展:

  • The company received FDA approval for broader labels for NEXLETOL and NEXLIZET in Q1, increasing their potential market to over 70 million patients in the U.S.

  • Esperion expects a positive decision from the European Commission on their European cardiovascular risk reduction label submissions by the end of Q2 2024.

  • A partnership with DSE for European tablet production is underway and should be complete by the second half of next year.

  • New commercial initiatives, such as the 'lipid lurkers' consumer campaign and promotional digital tools, have been launched and positively received.

  • Esperion intends to maintain their commercial plan and provide regular progress updates.

  • 該公司在第一季度獲得美國食品藥品管理局批准爲NEXLETOL和NEXLIZET提供更廣泛的標籤,將其潛在市場擴大到美國超過7000萬名患者。

  • Esperion預計,到2024年第二季度末,歐盟委員會將就其提交的歐洲心血管風險降低標籤做出積極決定。

  • 與DSE在歐洲平板電腦生產方面的合作正在進行中,並將於明年下半年完成。

  • 新的商業舉措,例如 “脂質潛伏者” 消費者活動和促銷數字工具,已經啓動並受到好評。

  • Esperion打算維持其商業計劃並定期提供最新進展。

更多詳情: Esperion 治療公司 IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論